Switching to systemic therapy after locoregional treatment failure: Definition and best timing

키워드

참고문헌 (54)

1. Bray F, "Global cancer statistics 2018 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J Clin, 68, pp.394~424 (2018)
2. Forner A, "Hepatocellular carcinoma", Lancet, 391, pp.1301~1314 (2018)
3. Villanueva A, "Hepatocellular carcinoma", N Engl J Med, 380, pp.1450~1462 (2019)
4. Omata M, "Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma : a 2017 update", Hepatol Int, 11, pp.317~370 (2017)
5. Marrero JA, "Diagnosis, staging, and management of hepatocellular carcinoma : 2018 practice guidance by the American Association for the Study of Liver Diseases", Hepatology, 68, pp.723~750 (2018)
6. European Association for the Study of the Liver, "EASL clinical practice guidelines: management of hepatocellular carcinoma", J Hepatol, 69, pp.182~236 (2018)
7. Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC, "2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma", Gut and Liver, 13(3), pp.227~299 (2019), 거트앤리버 소화기연관학회협의회[DOI]
8. Kokudo N, "Clinical practice guidelines for hepatocellular carcinoma : the Japan Society of Hepatology 2017(4th JSH-HCC guidelines)2019 update", Hepatol, 49, pp.1109~1113 (2019)
9. Llovet JM, "Sorafenib in advanced hepatocellular carcinoma", N Engl J Med, 359, pp.378~390 (2008)
10. Cheng AL, "Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma : a phase III randomised, doubleblind, placebo-controlled trial", Lancet Oncol, 10, pp.25~34 (2009)
11. Bruix J, "Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment(RESORCE) : a randomised, double-blind, placebo-controlled, phase 3 trial", Lancet, 389, pp.56~66 (2017)
12. Zhu AX, "Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib(REACH) : a randomised, double-blind, multicentre, phase 3 trial", Lancet Oncol, 16, pp.859~870 (2015)
13. Abou-Alfa GK, "Cabozantinib in patients with advanced and progressing hepatocellular carcinoma", N Engl J Med, 379, pp.54~63 (2018)
14. Kudo M, "Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma : a randomised phase 3 noninferiority trial", Lancet, 391, pp.1163~1173 (2018)
15. Park JW, "Global patterns of hepatocellular carcinoma management from diagnosis to death : the BRIDGE study", Liver Int, 35, pp.2155~2166 (2015)
16. Llovet JM, "Systematic review of randomized trials for unresectable hepatocellular carcinoma : chemoembolization improves survival", Hepatology, 37, pp.429~442 (2003)
17. Takayasu K, "Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients", Gastroenterology, 131, pp.461~469 (2006)
18. Takayasu K, "Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines", J Hepatol, 56, pp.886~892 (2012)
19. Matsui O, "Current status of hepatocellular carcinoma treatment in Japan: transarterial chemoembolization", Clin Drug Investig, 32(Suppl 2), pp.3~13 (2012)
20. Lencioni R, "Lipiodol transarterial chemoembolization for hepatocellular carcinoma : a systematic review of efficacy and safety data", Hepatology, 64, pp.106~116 (2016)
21. Varela M, "Chemoembolization of hepatocellular carcinoma with drug eluting beads : efficacy and doxorubicin pharmacokinetics", J Hepatol, 46, pp.474~481 (2007)
22. Lammer J, "Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma : results of the PRECISION V study", Cardiovasc Intervent Radiol, 33, pp.41~52 (2010)
23. Dhanasekaran R, "Comparison of conventional transarterial chemoembolization(TACE)and chemoembolization with doxorubicin drug eluting beads(DEB)for unresectable hepatocelluar carcinoma(HCC)", J Surg Oncol, 101, pp.476~480 (2010)
24. Golfieri R, "Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma", Br J Cancer, 111, pp.255~264 (2014)
25. Matsui O, "Interventional oncology : new options for interstitial treatments and intravascular approaches : superselective TACE using iodized oil for HCC : rationale, technique and outcome", J Hepatobiliary Pancreat Sci, 17, pp.407~409 (2010)
26. de Baere T, "Treatment of liver tumors with lipiodol TACE : technical recommendations from experts opinion", Cardiovasc Intervent Radiol, 39, pp.334~343 (2016)
27. Sieghart W, "Transarterial chemoembolization : modalities, indication, and patient selection", J Hepatol, 62, pp.1187~1195 (2015)
28. Raoul JL, "Updated use of TACE for hepatocellular carcinoma treatment : how and when to use it based on clinical evidence", Cancer Treat Rev, 72, pp.28~36 (2019)
29. Pua U, "Cone-beam CT acquisition during transradial TACE made easy; use of the swivel arm board", Br J Radiol, 91, pp.20170248~ (2018)
30. Liu FY, "Angio-computed tomograph-guided immediate lipiodol computed tomograph for diagnosis of small hepatocellular carcinoma lesions during transarterial chemoembolization", Chin Med J(Engl), 131, pp.2410~2416 (2018)
31. Piron L, "Radiation exposure during transarterial chemoembolization : angio-CT versus cone-beam CT", Cardiovasc Intervent Radiol, 42, pp.1609~1618 (2019)
32. Yamakado K, "Hepatic arterial embolization for unresectable hepatocellular carcinomas: do technical factors affect prognosis?", Jpn J Radiol, 30, pp.560~566 (2012)
33. Ogasawara S, "A randomized placebo-controlled trial of prophylactic dexamethasone for transcatheter arterial chemoembolization", Hepatology, 67, pp.575~585 (2018)
34. Peck-Radosavljevic M, "Outcomes of patients (pts) with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE): Global OPTIMIS final analysis", J Clin Oncol, 36(15_suppl), pp.4018~ (2018)
35. Miksad RA, "Liver function changes after transarterial chemoembolization in US hepatocellular carcinoma patients : the LiverT study", BMC Cancer, 19, pp.795~ (2019)
36. Hiraoka A, "Hepatic function during repeated TACE procedures and prognosis after introducing sorafenib in patients with unresectable hepatocellular carcinoma : multicenter analysis", Dig Dis, 35, pp.602~610 (2017)
37. Piscaglia F, "Patient selection for transarterial chemoembolization in hepatocellular carcinoma : importance of benefit", risk assessment, 2018, pp.7, 104~119
38. Kudo M, "Management of hepatocellular carcinoma in Japan : consensusbased clinical practice guidelines proposed by the Japan Society of Hepatology(JSH)2010 updated version", Dig Dis, 29, pp.339~364 (2011)
39. Kudo M, "Transarterial chemoembolization failure", refractoriness : JSHLCSGJ criteria 2014 update, 2014, pp.87(Suppl 1), 22~31
40. Raoul JL, "Evolving strategies for the management of intermediate-stage hepatocellular carcinoma : available evidence and expert opinion on the use of transarterial chemoembolization", Cancer Treat Rev, 37, pp.212~220 (2011)
41. Galle PR, "The treatment of intermediate stage tumours beyond TACE : from surgery to systemic therapy", J Hepatol, 67, pp.173~183 (2017)
42. Ogasawara S, "Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization", Oncology, 87, pp.330~341 (2014)
43. Arizumi T, "Effectiveness of sorafenib in patients with transcatheter arterial chemoembolization(TACE)refractory and intermediate-stage hepatocellular carcinoma", Liver Cancer, 4, pp.253~262 (2015)
44. El-Khoueiry AB, "Nivolumab in patients with advanced hepatocellular carcinoma(CheckMate 040) : an open-label, non-comparative, phase 1", 2 dose escalation and expansion trial, 2017, pp.389, 2492~2502
45. Zhu AX, "Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib(KEYNOTE-224) : a nonrandomised, open-label phase 2 trial", Lancet Oncol, 19, pp.940~952 (2018)
46. Johnson PJ, "Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma : results from the randomized phase III BRISK-FL study", J Clin Oncol, 31, pp.3517~3524 (2013)
47. Cainap C, "Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma : results of a randomized phase III trial", J Clin Oncol, 33, pp.172~179 (2015)
48. Finn RS, "Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC : additional analyses from the phase III RESORCE trial", J Hepatol, 69, pp.353~358 (2018)
49. Yoo C, "Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma", Invest New Drugs, 37, pp.567~572 (2019)
50. Ogasawara S, "Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma : a multicenter retrospective study in Japan", Invest New Drugs, 38, pp.172~180 (2020)
51. Arizumi T, "Time to transcatheter arterial chemoembolization refractoriness in patients with hepatocellular carcinoma in Kinki criteria stages B1and B2", Dig Dis, 35, pp.589~597 (2017)
52. Yasui Y, "Up-to-seven criteria as a useful predictor for tumor downstaging to within Milan criteria and Child-Pugh grade deterioration after initial conventional transarterial chemoembolization", Hepatol Res, 48, pp.442~450 (2018)
53. Eso Y, "Combination of Mac-2 binding protein glycosylation isomer and up-to-seven criteria as a useful predictor for Child-Pugh grade deterioration after transarterial chemoembolization for hepatocellular carcinoma", Cancers(Basel), 11, pp.405~ (2019)
54. Kudo M, "Lenvatinib as an initial treatment in patients with intermediatestage hepatocellular carcinoma beyond up-to-seven criteria and Child-Pugh a liver function: a proof-of-concept study", Cancers (Basel), 11, pp.1084~ (2019)

관련 논문AI추천